Engineering and characterization of a long half-life relaxin receptor RXFP1 agonist
S. C. Erlandson, J. Wang, H. Jiang, H. A. Rockman, A. C. Kruse
This study engineers a relaxin-2 variant with a longer serum half-life by fusing it with an antibody Fc fragment, maintaining RXFP1 agonist activity in vitro and in vivo.
bioRxiv · Apr 19, 2022Pharmacology & Toxicology